India: Are Known Substances Really A Patentable Subject Matter In Light Of Indian Patents Act, 1970


It is well stated in the Indian Patents Act, 1970 that grant of Product patent in India mainly in the areas of Pharmaceutical industry holds a relevance importance. In the last Patents (Amendment) Act, 2005 which is deemed to be revolutionized patent regime in India, amendment incorporated the provision of granting product patents in India. With the commencement of the amendment Act, patent protection in the fields of food, pharma, and drug products is now readily possible. The Indian patent practice relating to the patenting of food, medicine and drug products or biological material is relatively new and thus not so well established. Considering all patenting issues after the 2005 amendment, one of the major issue of this new regime is whether the discovery of a new use of a known substance or pharmaceutical composition would be entitled to a patent protection or not. Now with this article we discuss the issue of patentability of a new or subsequent medical use of a compound or composition wherein the first medical use of same is already known.

From the Indian Perceptive:

With the execution of Indian Patents (Amendment) Act, 2005, it is now possible to obtain patent protection on a substance intended to be used or capable of being used as a medicine or drug. According to section 3 (d) of the Act, "the mere discovery of a new form of a known substance which does not result in the enhancement of the known efficacy of that substance or the mere discovery of any new property or new use for a known substance or of the mere use of a known process, machine or apparatus unless such known process results in a new product or employs at least one new reactant."1

Moreover, to obtain a patent for the second and subsequent use of a medicament the therapeutic efficacy must be enhanced or at least a new reactant must be employed in its manufacture. Section 3(d) clearly indicates that a substance or a composition must be novel, should involve an inventive step and should be capable of industrial application, whereas, swiss-type claim format deviates from the rule of absolute novelty. The discovery of previously unrecognized useful property of a drug is not considered novel in India and hence is not patentable. This section of the act makes it clear that swiss-type claims are not accepted for patent protection in India. An improvement made to a known substance does not qualify for patent protection in India.

The Act considers salts, esters, ethers, polymorphs, metabolites, pure form, particle size, isomers, mixtures of isomers, complexes, combinations and other derivatives of known substance to be the same substance, unless they differ significantly in properties with regard to efficacy. In India only a new chemical entity or a new molecule entity is granted protection. Formulations, such as, combinations of pharmaceuticals, changes in dosage form, new use of a known medicament, etc, are considered not patentable as there is lack of inventive step.

The Scope of Patentability of New Use of a Known Substance or Composition- From US and EPO perceptive

There are different opinions regarding patentability of second and subsequent medical uses of known substances or pharmaceutical compositions. Under the Patent Laws of various countries, discovery of a new advantage of a known substance or pharmaceutical composition is considered as a new invention that qualifies to be patentable.

As per United States Patents Law US Code 101 "whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefore, subject to the conditions and requirements of this title."2 The claims addressed at the method of treatment are accepted in US, therefore it alleviates the need of swiss-type claim format. However US patent and Trademark Office (USPTO) accepts swiss-type claims.

According to Section 4A (3) of the United Kingdom (UK) Patents Act 1977 (as amended), "in the case of an invention consisting of a substance or composition for use in any such method, the fact that the substance or composition forms part of the state of the art shall not prevent the invention from being taken to be new if the use of the substance or composition in any such method does not form part of the state of the art."3 That is to say, the UK Patents Act regarded discovery of a new purpose of a known drug to be novel. The second and subsequent use of a known drug was not considered as lacking in novelty if the subsequent use did not form a part of the state-ofthe- art. In Wyeth's Application [1985] RPC 545, one of the claims was drafted in the swiss-type format for patenting a new therapeutic use of a known drug which was refused by the examiner and later permitted by the UK Patents court on an appeal.

In a post G2/08 practice note issued by the UK Intellectual Property Office (IPO) the swiss-type claim format was prohibited from use in any UK patent application without any equivalent "grace period". Moreover, from the issuance of G2/08 the swisstype claim format claiming second or subsequent medical use of a known drug was objected to by the UK IPO on the ground of lack of clarity.

Use of swiss type Claim method:-

Swiss type claims The origin of 'swiss-type claim format' is supported by the fact that the 'discovery of new use of a known drug' by a pharmaceutical company employs time, money and labor which makes the 'new use' equally worthy of patent protection as compared to the original research which established the first pharmaceutical use of that drug. To tackle the issue of establishing the 'Novelty of Purpose,' the European Patent Office and the Swiss Patent Office adopted the swiss-type claim format. The use of this form of claim format is derogation from the obligation for absolute novelty. Its format is "Use of substance X in the preparation of a medicament for the treatment of disease Y."

The reasons for exclusion

The basis for the exclusion of 'new use of already known chemical entity' from patentability is that it might lead to ever greening of that chemical entity. Through ever greening companies try to secure patents on large numbers of complex and often highly speculative patents through minor modifications, when the original patent over the active compound of a brand-name drug is due to expire. These subsequent patents cover different forms of the substance or minor variation and everything from aspects of the manufacturing process to tablet color, or even a chemical produced by the body when the drug is ingested and metabolized by the patient.

By ever greening the multinational pharmaceutical companies are retaining profits from their blockbuster drugs for long as possible. Pharmaceutical giants in countries like US adopt the swiss-type claim format as a monopolization strategy to evergreen their patented drugs.


It is clear from the Indian Patents Act, 1970, which mandates that for being patentable a substance or a composition must be novel, should involve an inventive step and should be capable of industrial application, whereas, swiss-type claim format deviates from the rule of absolute novelty. As per s. 3(d) of the Act, to obtain a patent for the second and subsequent use of a medicament, the therapeutic efficacy must be enhanced or at least a new reactant must be employed in its manufacture.

The stringent approach of Indian patent law towards the exclusion of swiss-type claim format has made the pharmaceutical industries reluctant towards further improvement of a known drug or discovery of new therapeutic use of a known substance. It is clear from the above paragraphs and discussions, that pharmaceutical research does not halt on patenting of one pharmaceutical activity mainly due to ongoing research the same drug may be found to have other beneficial properties which was previously unrecognized. Therefore, from the viewpoint of a pharma industry the exemption of swiss-type claim format in India is unwelcoming and would rather harm to the Industry.





The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions